Oncology Drugs Experience Sales Slowdown In U.S.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
oncology
GE Healthcare to Acquire Diagnostics Company Clarient
General Electric announced Friday that its healthcare unit will acquire molecular diagnostics company Clarient in a deal worth approximately $580 million.
Genomics Researchers Have a Bone to Pick with Multiple Myeloma
Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
China Analyst Identifies 10 Pharma Stocks with Highest Growth Potential
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
Ascalon Leverages Experienced Management Team, Strategic Partnerships for Cancer Drug Development
Ascalon International is a privately held oncology-focused drug development company based in Scottsdale, Arizona.
Adventrx Pharmaceuticals Seeks to Improve Current Cancer Drugs
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
For Advaxis, Bacteria Help More Than They Hurt
The idea of using harmful bacteria to treat disease might strike many as an odd concept.
[OneMedForum] Senesco Technologies: Life and Death on a Cellular Level
“Programmed cell death” sounds a bit sinister, but it’s actually a normal and healthy process.
Inovio BioMedical at the 2010 OneMedForum
Dr. Joseph Kim, CEO and President of Inovio Biomedical, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Augmenix at the 2010 OneMedForum
Bradley Poff, General Manager of Augmenix, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.